Twist (TWST) Q3 2025 Earnings Transcript

Twist Bioscience reported record Q3 revenue of $96.1 million, up 18% year over year, with gross margin expanding to 53.4% from 43.3% and adjusted EBITDA loss improving by $14 million to $8 million. Full-year revenue guidance was narrowed higher to $374 million-$376 million, while gross margin guidance was lifted to 50.5%-51% and management reiterated a path to adjusted EBITDA breakeven in 2026. The upbeat quarter was partially offset by a disclosed $5 million NGS customer transition headwind in Q4 and some Q1 impact, but the overall operational and margin trajectory was clearly constructive.

Analysis

TWST is transitioning from a story of product-market fit to one of operating leverage plus optionality. The key second-order effect is that margin expansion is now making every incremental customer acquisition and product launch more financially meaningful, so the market should start valuing the revenue mix shift more than headline growth volatility. That matters because the company’s real moat is not any single assay; it is the ability to translate a broad installed base into repeatable launch cadence with rising contribution per dollar of sell-through.

The near-term overhang is mostly mechanical, not fundamental: one large NGS account creates a visible Q4/Q1 air pocket, which can compress multiple despite continued underlying momentum. That setup usually creates a better entry than chasing strength, because the revenue trough is time-bound while the commercialization step-up is multi-year. If management executes through the transition, the market will likely re-rate TWST on normalized growth and EBITDA trajectory rather than quarter-to-quarter revenue cadence.

The more interesting contrarian point is that SynBio is probably being underwritten too conservatively if investors still anchor on the prior large-contract comparison. The incremental economics now look close to NGS, so product launches like adapter-free fragments can be disproportionately accretive if they improve turnaround time and share in fragmented end markets. The risk is that higher-margin optimism becomes a substitute for actual demand elasticity; if academic and industrial budgets soften further, the company could see mix help fade just as it ramps reinvestment.

Overall, the setup is bullish over 6-12 months but not clean over the next 1-2 quarters. TWST is increasingly a self-funding growth platform, yet the stock may need a consolidation phase while the market digests the temporary NGS normalization and waits for proof that new product launches convert into sustained bookings, not just trial activity.

Key Decisions for Investors

• Go long TWST on a pullback into the Q4 air pocket; target a 6-12 month hold. Risk/reward favors entry after the market prices in the ~$5M NGS normalization, since the reset is temporary while margin gains are structural.
• Buy TWST Jan-2026 or Mar-2026 call spreads rather than outright calls to express upside into EBITDA breakeven with capped premium outlay. The spread should benefit if investors start valuing normalized FY26 growth and sustained >50% gross margin.
• Pair trade: long TWST / short a slower-growth life science tools name with lower product-launch optionality and less operating leverage. The thesis is that TWST’s incremental margin conversion and launch cadence should drive multiple expansion faster than peers over the next 2-4 quarters.
• If already long, hedge near-term event risk by selling covered calls against a core TWST position into strength ahead of Q1 guidance season. This monetizes elevated volatility around the revenue normalization without abandoning the structural bull case.
• Watch for confirmation in FY26 MRD and FlexPrep adoption; add on any dip only if management shows sequential order acceleration. If those launches fail to convert, the stock likely remains range-bound despite gross margin upside.